| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 19, 2002
From the Department of Hypertension and Cardiorenal
Medicine, Dokkyo University School of Medicine (Y.M., T.N., N.K., H.O.,
H.M.), Mibu, Tochigi; and the Research Institute National
Cardiovascular Center (K.K.), Suita, Osaka,
Japan. * To whom correspondence should be addressed. E-mail: nishikim{at}dokkyomed.ac.jp.
AbstractPrevious
studies have demonstrated that adrenomedullin has
inhibitory effects on the proliferation and DNA synthesis
of mesangial cells and vascular smooth muscle cells in
vitro and that plasma adrenomedullin levels are markedly elevated in
malignant hypertension. This study was designed to examine whether
chronic adrenomedullin infusion has renoprotective effects in malignant
hypertensive rats. We studied the following 3 groups: control Wistar
Kyoto rats, deoxycorticosterone acetate--salt spontaneously
hypertensive rats, and adrenomedullin-treated deoxycorticosterone
acetate--salt spontaneously hypertensive rats. Chronic adrenomedullin
infusion using an osmotic minipump was started
simultaneously with deoxycorticosterone acetate--salt
treatment. After 3 weeks of the treatment, malignant hypertensive rats
were characterized by higher blood pressure, kidney weight, urinary
protein excretion, glomerular injury score, plasma renin
concentration, aldosterone level, endogenous
rat plasma adrenomedullin level, renal cortical tissue
angiotensin II level, angiotensin-converting
enzyme mRNA level, and transforming growth factor-ß1 mRNA level in
the renal cortex, and by lower creatinine clearance,
compared with the control rats. Chronic adrenomedullin infusion
significantly improved these parameters (kidney weight
-6.5%, urinary protein excretion -63.8%, glomerular
injury score -38.3%, plasma renin concentration -52.4%,
aldosterone -23.2%, rat adrenomedullin -28.6%, renal
angiotensin II -28.1%, renal
angiotensin-converting enzyme mRNA -38.3%, renal
transforming growth factor-ß1 mRNA -56.2%, and
creatinine clearance +20.5%) without significant reduction
of mean arterial pressure (-4%). Kaplan-Meier survival
analysis showed that adrenomedullin infusion significantly
prolonged survival time. These results suggest that subdepressor dose
of chronic adrenomedullin infusion has renoprotective effects in this
malignant hypertension model, at least in part, via inhibition of the
circulating and intrarenal renin-angiotensin
system.
Revised on March 7, 2002
Long-Term Adrenomedullin Infusion Improves
Survival in Malignant Hypertensive Rats
Yosuke Mori;
This article has been cited by other articles:
![]() |
R. Norregaard, T. Bodker, B. L. Jensen, L. Stodkilde, S. Nielsen, and J. Frokiaer Increased renal adrenomedullin expression in rats with ureteral obstruction Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R185 - R192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahman, A. Nishiyama, P. Guo, Y. Nagai, G.-X. Zhang, Y. Fujisawa, Y.-Y. Fan, S. Kimura, N. Hosomi, K. Omori, et al. Effects of Adrenomedullin on Cardiac Oxidative Stress and Collagen Accumulation in Aldosterone-Dependent Malignant Hypertensive Rats J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1323 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ishikawa, T. Nishikimi, K. Akimoto, K. Ishimura, H. Ono, and H. Matsuoka Long-Term Administration of Rho-Kinase Inhibitor Ameliorates Renal Damage in Malignant Hypertensive Rats Hypertension, June 1, 2006; 47(6): 1075 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fukuhara, A. Sakurai, H. Sano, A. Yamagishi, S. Somekawa, N. Takakura, Y. Saito, K. Kangawa, and N. Mochizuki Cyclic AMP Potentiates Vascular Endothelial Cadherin-Mediated Cell-Cell Contact To Enhance Endothelial Barrier Function through an Epac-Rap1 Signaling Pathway Mol. Cell. Biol., January 1, 2005; 25(1): 136 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Luodonpaa, H. Leskinen, M. Ilves, O. Vuolteenaho, and H. Ruskoaho Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2004; 286(6): R1085 - R1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sandner, K. H. Hofbauer, H. Tinel, A. Kurtz, H. C. Thiesson, P. D. Ottosen, S. Walter, O. Skott, and B. L. Jensen Expression of adrenomedullin in hypoxic and ischemic rat kidneys and human kidneys with arterial stenosis Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R942 - R951. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishikimi, F. Yoshihara, S. Horinaka, N. Kobayashi, Y. Mori, K. Tadokoro, K. Akimoto, N. Minamino, K. Kangawa, and H. Matsuoka Chronic Administration of Adrenomedullin Attenuates Transition From Left Ventricular Hypertrophy to Heart Failure in Rats Hypertension, November 1, 2003; 42(5): 1034 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M.C. Dixon A new altruist on the block: effects of adrenomedullin after myocardial infarction Cardiovasc Res, December 1, 2002; 56(3): 347 - 349. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |